PRoFESS was meant to compare telmisartan with placebo, as well as to compare ASA+dipyridamol vs. clopidogrel in rates of secondary stroke.
The Aggrenox arm had no significant difference in secondary stroke prevention than the Plavix arm. Additionally, there was no significant difference in hemorrhagic complications between the two arms. Aggrenox was more poorly tolerated, with higher complaints of side-effects, and poorer adherence to the trial regimen.
If Plavix has the same risk-benefit ratio as Aggrenox, and your patient is more likely to tolerate and adhere to the treatment regimen, then why prescribe Aggrenox at all?